Moreover, CAR-T cell therapies directed against FRα or FRβ have been explored using different antibodies and CAR constructs in human tumor xenograft models of ovarian cancer (22, 23), triple-negative breast cancer (TNBC) (24), gastric cancer (25), and AML (17). This evidence concerns the gene FOLR2 and ovarian carcinoma.